EPRX
EUPRAXIA PHARMACEUTICALS INC.BS score 18.8LOWPHASE2 · mkt cap $435.4M · rev ttm $0
drug hypothesis
EP-104IAR modulates Not explicitly stated in provided data - appears to be intra-articular treatment for osteoarthritis but specific molecular target not specified to treat Osteoarthritis of the knee.
moa:Not explicitly stated in provided data - appears to be an intra-articular (IAR) injection for symptomatic relief of knee osteoarthritis pain
score breakdown
trial design0
base rate disconnect17
language red flags60
composite18.8
valuation analysis
market cap$435.4M
revenue ttm$0
phasePHASE2
historical base rate15%
disconnect ratio0.6x
lead trialNCT05608681
meta
cik0001581178
first discovered2026-04-09
last updated2026-04-10
statusACTIVE
llm model—
extracted at2026-04-10
trial design
Phase 2, randomized, quadruple-blind, placebo-controlled trial. 318 patients enrolled. Two arms: EP-104IAR 25 mg vs Vehicle (saline control). Primary completion date: 2023-05-17.
primary endpoint:Difference in Change From Baseline Between EP-104IAR and Vehicle in WOMAC Pain Subscale at 12 weeks
claimed differentiation
Not provided in clinical trial data - no SEC filing text included in request
language red flags
- Target and mechanism of action not disclosed in trial registration data - unusual for a drug in Phase 2
- No preclinical data or differentiation claims visible in provided data - cannot assess company's positioning
- Trial data alone does not contain information on company's SEC filing claims or risk disclosures - request appears to include only clinical trial NCT data without accompanying SEC filing text
company-stated risks
- Not explicitly stated in provided clinical trial data
upcoming catalysts
- Q2-Q3 2023 (since primary completion was 2023-05-17)Topline results release
- Not specified in provided dataPotential NDA submission or further trial initiation